METHODS: We conducted a systematic review and meta-analysis of studies published from 2010 to 2025 comparing anti-VEGF agents (bevacizumab, ranibizumab, aflibercept) with laser therapy in preterm infants with treatment-requiring ROP. This evidence concerns the gene VEGFA and retinopathy of prematurity.